MLTX NASDAQ
MoonLake Immunotherapeutics
1W: +15.6%
1M: +3.2%
3M: -35.1%
YTD: -0.2%
1Y: +25.3%
3Y: -78.3%
5Y: +20.3%
$11.93
+0.12 (+1.02%)
Weekly Expected Move ±10.7%
$9
$11
$12
$13
$14
Credit Risk of going bust: higher than 59% of companies Debt: 9.1% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.16 (down 99%), MoonLake Immunotherapeutics would be worth roughly what it owes.
Total debt $101.5M against a stock market value of $1.02B.
Distance to default 4.28 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $49.8M (short-term plus half of long-term), stock volatility 70.4%; Altman Z'' 2.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $101.5M against a stock market value of $1.02B.
Distance to default 4.28 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $49.8M (short-term plus half of long-term), stock volatility 70.4%; Altman Z'' 2.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
📊 Key Metrics
TTM$0M
Revenue
+0.0% YoY
$-264M
Net Income
-49.7% YoY
$-225M
Free Cash Flow
-35.0% YoY
0.0%
Gross Margin
0.0%
Op. Margin
0.0%
Net Margin
💰 Income Flow
How revenue becomes profit💵 Cash Flow
⚠️ Cash Burn Where cash goes🏦 Balance Sheet
Assets = Liabilities + Equity📈 Financial Health
Profitability
ROE-67.4%
ROA-51.0%
ROIC2902.7%
Valuation
P/E-3.1
P/B2.1
EV/EBITDA-4.0
Leverage
Debt/Equity0.24
Current Ratio12.56
Interest Cov.-25.2x
Quality Scores
Piotroski F1/9
Altman Z4.11
Beneish M0.00